Abstract 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT) has long been considered a by-product of thromboxane A 2 (TxA 2 ) biosynthesis with no biological activity. Recently, we reported 12-HHT to be an endogenous ligand for BLT2, a low-affinity leukotriene B 4 receptor.
INTRODUCTION
12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT) was identified as a product of prostaglandin H 2 (PGH 2 ), which is biosynthesized from arachidonic acid. Until recently, 12-HHT has been considered merely a by-product of thromboxane A 2 (TxA 2 ) biosynthesis (1) . The cleavage of PGH 2 into 12-HHT and malondialdehyde (MDA) is catalyzed by thromboxane A synthase (TxAS), the enzyme responsible for TxA 2 biosynthesis (2, 3) . During aggregation of human and mouse platelets, 12-HHT and TxA 2 are produced in a 1:1 ratio in larger amounts than other prostaglandins (PGs) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Non-enzymatic conversion of PGH 2 to 12-HHT in vitro has also been reported to occur via a process that involves glutathione and heme (13). Although PGs and TxA 2 mediate various physiological and pathophysiological roles in many tissues and cells through the activation of their specific G-protein coupled receptors (GPCRs), the biological roles of 12-HHT have yet to be elucidated (1) . By contrast, the biological roles of TxA 2 have been studied in detail. TxA 2 stimulates platelet aggregation and increases blood pressure by inducing the contraction of vascular smooth muscles through activation of the TxA 2 -specific GPCR, TP (14). For these reasons, ozagrel, an inhibitor of TxAS, is used clinically as a therapeutic drug to improve brain blood circulation after brain hemorrhage (15).
37°C for the indicated times, the blood was centrifuged at 5,000 × g for 10 min to separate the serum fraction. A 50 µl volume of serum was immediately mixed with 100 µl of methanol containing 0.1% formic acid and a mixture of deuterium-labeled eicosanoids, which served as internal standards. To prepare washed platelets, 36 ml of human blood was collected into 4 ml of 3.2% sodium citrate. Platelet-rich plasma (PRP) was obtained by centrifugation at 200 × g for 10 min. Platelets were isolated from PRP by centrifugation at 1,000 × g for 10 min, washed twice with calcium free HEPES-Tyrode's buffer (134 mM NaCl, 0.34 mM Na 2 HPO 4 , 2.9 mM KCl, 12 mM NaHCO 3 , 20 mM HEPES, 5 mM glucose, 1 mM MgCl 2 , pH 7.4), and resupended in calcium free HEPES-Tyrode's buffer.
Production of 12-HHT and eicosanoids in thrombin-treated washed platelets -Human
washed platelets (2 × 10 5 cells/100 µl) in calcium free HEPES-Tyrode's buffer were prewarmed for 5 min at 37°C. Reactions were initiated by the addition of 50 µl of thrombin (0.5 NIH unit/mL) in HEPES-Tyrode's buffer (134 mM NaCl, 0.34 mM Na 2 HPO 4 , 2.9 mM KCl, 12 mM NaHCO 3 , 20 mM HEPES, 5 mM glucose, 1 mM MgCl 2 , 1.8 mM CaCl 2 , pH 7.4), incubated at 37°C, and terminated by the addition of 150 µl of ice-cold methanol containing 0.1% formic acid and a mixture of deuterium-labeled eicosanoids.
RT-PCR -Isogen-LS (Nippon Gene) was used to extract total RNA from mouse whole blood as described by the manufacturer's instruction. Total RNA (1 µg) was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen). An equal quantity of cDNA was used to amplify TxAS and beta-actin transcripts using the following conditions: 94°C for 15 sec, 58°C for 30 sec, and 68°C for 1 min for a total of 35 cycles (for TxAS), or 94°C for 15 sec, 58°C for 30 sec, and 68°C for 45 sec for a total of 30 cycles (for beta-actin). The sequences of the primers used are as follows: TxAS, 5'-GACCAGCAAAGCAGCAGAAGAGAG-3' (forward) and 5'-AGGTATGTGAACGGCCTCCG-3' (reverse); beta-actin 5'-GTGGACCTCATGGCCTACAT-3' (forward) and 5'-GGGTGCAGCGAACTTTATTG-3'
(reverse). The polymerase chain reaction (PCR) products were analyzed by electrophoresis on a 2% agarose gel.
Preparation of mouse serum -Mouse blood was collected from the caudal vena cava under urethane anesthesia and incubated at 37ºC for 0, 1, 2, 3 and 5 min. After centrifugation at 5,000 × g for 10 min at 4ºC, the supernatant was recovered as serum. From this, 10 µl was immediately mixed with 20 µl of methanol containing 0.1% formic acid and a mixture of deuterium-labeled eicosanoids as internal standards.
Plasmids -Complementary DNA (cDNA) of human COX-1 and COX-2 were a gift from Dr.
Murakami (The Tokyo Metropolitan Institute of Medical Science). The ORF of COX-1 was amplified by PCR using a sense primer (5' -AAGATATCATGAGCCGGAGTCTCTTG-3') and an antisense primer (5'-TTTCTCGAGTCAGAGCTCTGTGGATGG-3'), digested with EcoRV and XhoI, and subcloned into the EcoRV-XhoI site of pCXN2.1 (+) (20). The ORF of COX-2 was amplified by PCR using a sense primer (5'-AAGGTACCATGCTCGCCCGCGC-3') and an antisense primer (5'-TTGAATTCTACAGTTCAGTCGAACGTTC-3'), digested with KpnI and Western blotting analysis -HEK293 cells transfected with each expression vector were lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.25% sodium deoxycholate, 1% NP-40, 1 mM AEBSF, 0.8 µM aprotinin, 15 µM E-64, 20 µM leupeptin, 50
µM bestatin, and 10 µM pepstatin A), and then centrifuged at 10,000 × g for 10 min at 4ºC. The supernatants were recovered and protein concentrations were determined using a BCA assay kit (Nacalai Tesque). Proteins were diluted in SDS sample buffer (37.5 mM Tris-HCl, 7.5% glycerol,
1.5% SDS, 1.5% 2-mercaptoethanol, and 0.075% bromophenol blue). Samples were then denatured for 5 min at 95ºC, electrophoresed in 10% SDS-polyacrylamide gels, and transferred to PVDF membranes. After blocking with 1% skim milk in Tris-buffered saline (TBS), the membranes were incubated with primary antibodies against COX-1, COX-2, or TxAS
(1:250-1:1000 dilution in TBS), and then with horseradish peroxidase-conjugated secondary antibodies (1:5000 dilution). After washing with TBS-T, the membranes were visualized with a chemiluminescence reagent kit (PerkinElmer) and an LAS-4000 mini imaging system (Fujifilm). (Thermo Fisher Scientific) were used. An aliquot of each sample (50 µl) was injected into the trap column, an Opti-Guard Mini C18, at a total flow rate of 500 µl/min. Three minutes after sample injection, the valve was switched to introduce the trapped sample to the analytical column, a Capcell Pak C18 MGS3 (Shiseido, Tokyo, Japan). Separation of lipids was achieved by a step gradient using mobile phase A and mobile phase B at ratios of 64:36 (0-6 min), 55:45 (6-7 min), and 35:65 (7-13 min). The compositions of mobile phases A and B were MeCN:formic acid (100:0.1) and water:formic acid (100:0.1), respectively. The total flow rate was 120 µl/min, the column temperature was set at 46°C, and the LC column eluent was introduced directly into a TSQ Quantum Ultra. All compounds were analyzed in a negative ion polarity mode. 12-HHT and eicosanoids were quantified by selective reaction monitoring (SRM).
Production of 12-HHT and eicosanoids in HEK293 cells
The SRM transitions monitored were m/z 279 → 179 for 12-HHT, m/z 369 → 195 for TxB 2 , and m/z 351 → 271 for PGE 2 and PGD 2 . For accurate quantification, a mixture of deuterium-labeled eicosanoids was used as the internal standard. As deuterium-labeled 12-HHT was not available, 12-HHT was calibrated using deuterium-labeled LTB 4 . Automated peak detection, calibration, and calculation were carried out by the Xcalibur 1.2 software package.
RESULTS

Production of 12-HHT and TxB 2 during blood coagulation
Previous studies have shown that 12-HHT is abundantly produced during blood coagulation (23, 24). To confirm this, we collected human blood from three healthy volunteers and measured 12-HHT and eicosanoid levels during blood coagulation ( We also examined the involvement of COX and TxAS in 12-HHT production during blood coagulation. Pretreatment of human whole blood with aspirin, a COX inhibitor, inhibited 12-HHT and TxB 2 production in a dose-dependent manner, with a concentration of 10 µM aspirin inducing almost complete inhibition of 12-HHT and TxB 2 production (Fig. 1C) .
Pretreatment of blood with ozagrel, an inhibitor of TxAS, also inhibited 12-HHT and TxB 2 production in a dose-dependent manner. Although 10 µM ozagrel almost completely inhibited TxB 2 production, 12-HHT production was only partially inhibited ( Fig. 1D and E). Ozagrel treatment at 10 µM also increased the production of PGD 2 and PGE 2 ( Fig. 1E ). The effects of heparin, aspirin, and ozagrel were similarly observed among three volunteers (Fig. 1 , SFig. 1 and
SFig. 2).
Production of 12-HHT and TxB 2 in human platelets
Next, we examined thrombin-stimulated production of 12-HHT and eicosanoids in washed human platelets from two volunteers basically with similar results ( Fig. 2 and SFig. 3).
Expression of COX-1 and TxAS in human platelets was confirmed by western blotting (data not shown). Thrombin treatment stimulated 12-HHT production in a time-dependent manner, and the level of 12-HHT (40 pmol/ 10 7 platelets) was higher than that of TxB 2 (25 pmol/ 10 7 platelets) at 300 seconds after stimulation ( Fig. 2A) . Thrombin stimulation also resulted in PGD 2 and PGE 2 production, although the amounts of PGD 2 and PGE 2 were much lower than those of 12-HHT and TxB 2 ( Fig. 2A) . Treatment of human platelets with 10 µM ozagrel almost completely inhibited thrombin-induced TxB 2 production, but 12-HHT production was inhibited by 40 to 60% ( Fig. 2B and SFig. 3B). Conversely, production of PGD 2 and PGE 2 was markedly increased by ozagrel treatment. These results suggest that two biosynthetic pathways of 12-HHT production, TxAS-dependent and -independent, are present in human platelets, and that ozagrel treatment increases PGD 2 and PGE 2 production by shunting PGH 2 to PGD 2 and PGE 2 synthetic pathways.
12-HHT production is partially inhibited by TxAS deficiency
We next measured the production of 12-HHT and eicosanoids during blood coagulation in TxAS-deficient mice. The lack of TxAS expression in TxAS -/-mice was first confirmed by
RT-PCR analysis of whole blood cells (Fig. 3A) . Next, whole blood was collected from wild-type (WT) and TxAS-deficient mice, and 12-HHT and eicosanoid levels were measured in the serum. In WT mouse serum, the concentrations of 12-HHT and TxB 2 increased in a time-dependent manner, and reached maximum concentrations of 286 and 268 nM, respectively, after 10 min of incubation (Fig. 3B ). In the serum from TxAS -/-mice, 50 nM 12-HHT was detected after 60 min of incubation, while no TxB 2 was detected (Fig. 3B ). In addition, PGE 2 and PGD 2 levels in the serum of TxAS -/-mice were significantly higher than in the serum of WT mice. These results indicate that 12-HHT is produced during blood coagulation in mice in a similar manner to that in humans (Fig. 1A , SFig. 1A and SFig. 2A). These results also show that significant amounts of 12-HHT are biosynthesized in the blood even in the absence of TxAS, and suggest that accumulated PGH 2 caused by TxAS deficiency is used for the production of PGD 2 and PGE 2 .
Involvement of COX-1 and TxAS
To examine the contribution of TxAS and COXs to the production of 12-HHT, we measured ozagrel before the addition of arachidonic acid. In cells expressing both COX-1 and TxAS, pretreatment with 10 µM ozagrel only partially inhibited 12-HHT production, while TxB 2 production was completely inhibited (Fig. 4C ). In addition, 12-HHT production was not affected by pretreatment with ozagrel in cells expressing only COX-1 (Fig. 4C, 12-HHT) . These results
show that TxAS catalyzes the production of 12-HHT from PGH 2 produced by COX-1 and that 12-HHT is produced by TxAS-dependent and -independent pathways.
Involvement of COX-2 and TxAS
We then performed similar experiments using COX-2 and TxAS. 12-HHT production was observed in COX-2-expressing cells with or without TxAS after the addition of 10 µM arachidonic acid (Fig. 5A, 12-HHT) . Interestingly, 12-HHT production in cells expressing COX-2 alone was higher than in cells expressing both COX-2 and TxAS (Fig. 5A , 12-HHT).
TxB 2 production was observed only in cells co-transfected with COX-2 and TxAS (Fig. 5A , TxB 2 ), and PGE 2 production was detected only in cells expressing COX-1 alone (Fig. 5A , PGE 2 ).
These results also suggest that TxAS is not required for 12-HHT production, but is vital for TxB 2 production in COX-2-expressing cells, as is the case for COX-1-expressing cells. To confirm
TxAS-independent production of 12-HHT, HEK293 cells were pretreated with ozagrel. In cells expressing both COX-2 and TxAS, pretreatment with 10 µM ozagrel did not inhibit 12-HHT production but completely inhibited TxB 2 production (Fig. 5B) . Pretreatment with ozagrel also increased PGE 2 production, suggesting that accumulated PGH 2 was used for the production of PGE 2 ( Fig. 4B and 5B). 12-HETE production was not affected by the pretreatment with ozagrel, suggesting that the 12-lipoxygenase pathway is independent of the COX-pathway. These results indicate that TxAS is indispensable for TxA 2 production, but not for 12-HHT production.
TxAS-independent production of 12-HHT from PGH 2
To confirm TxAS-independent 12-HHT production, we next examined the conversion of PGH 2
into TxB 2 and 12-HHT using heat-denatured homogenate of HEK293 cells (Fig. 6) However, the physiological roles and biosynthetic pathway of 12-HHT remain elusive.
In this report, we show that 12-HHT is produced by both TxAS-dependent and -independent pathways in vitro and in vivo using LC-MS/MS. Until now, the non-enzymatic conversion of 12-HHT from PGH 2 by heme or reduced glutathione had been reported only in an in vitro cell-free system (13, 29). Yu et al. reported the successful establishment of TxAS-deficient mice with normal thrombopoiesis and lymphocyte differentiation (30), and examined 12-HHT production by washed platelets stimulated with [ 14 C] arachidonic acid (AA) using thin-layer chromatography (TLC). Although they reported that the amount of 12-HHT in TxAS -/-platelets was reduced but not completely lost, they did not address this issue in detail. In this report, we used LC-MS/MS to quantify simultaneously the levels of 12-HHT and various eicosanoids using TxAS-deficient mice. During blood coagulation, 12-HHT levels reached concentrations of 500 to 900 nM (human blood) and 300 nM (mouse blood), which are high enough to activate endogenous BLT2, a GPCR for 12-HHT (16). In the blood of volunteers-1 and -3, the levels of 12-HHT were higher than that of TxB 2 ( Fig. 1A and SFig. 2A), and the level of 12-HHT was comparable to TxB 2 in volunteer-2 (SFig. 1A). These individual differences might be due to the different expression levels of TxAS in platelets. In fact, volunteer-2's blood produced larger amount of TxB 2 and 12-HHT (SFig. 1A) than volunteers-1 and -3 ( Fig. 1A and SFig. 2A), and the individual difference of TxB 2 and 12-HHT generation requires future analyses. Although we did not confirm the chirality of 12-HHT in our study, it is reasonable to assume that non-enzymatically generated 12-HHT is 12(S)-HHT, based on the chirality of PGH 2 . Our results are important, because this is the first report to quantitatively show the TxAS-independent 12-HHT production using TxAS-deficient mice. Recently, Bui et al. reported that cytochrome P450 protein, CYP2S1 is able to metabolize PGG 2 and PGH 2 to 12-HHT (31). Further study is required to identify the other 12-HHT producing enzymes.
The other important finding of this study is the possible functional coupling of COX and TxAS enzymes. TxAS deficiency or ozagrel treatment caused a compensatory increase in PGD 2 and PGE 2 levels (Fig. 3B, Fig. 4B , 4C, and Fig. 5 ). These results strongly suggest that in the absence or inhibition of TxAS, PGH 2 produced from AA by COX is shunted into PGE 2 and PGD 2 , possibly through non-enzymatic pathways. This is supported by the findings that PGH 2 is rapidly converted to 12-HHT, PGD 2, and PGE 2 through synthetic pathways in aqueous solutions (data not shown), and that the expression levels of other PG-producing enzymes are low in platelets and HEK cells.
The contribution of TxAS for 12-HHT generation seems to be greater in whole blood ( Fig. 1 and 2) and platelets (Fig. 3) than in COXs and TxAS transfected HEK cells (Fig. 4 and 5 The use of TxAS inhibitors as antithrombotic agents offers an advantage over aspirin in that they redirect arachidonic metabolism toward PGI 2 and other protective eicosanoids. However, the therapeutic effects of these agents has been disappointing (32), partly because inhibition of TxAS also results in accumulation of PGH 2 , which can activate TP receptors at higher concentrations (30). Although dual inhibition of TxAS and TP may be a potential treatment option (33), the unexpected production of PGs observed in this study might evoke some side effects associated with TxAS inhibitors, including headache and fever. Lipidomics analysis using LC-MS/MS will be a useful tool to monitor the changes in metabolic pathways induced by inhibitors of enzymes of the arachidonic cascade.
In summary (Fig. 7) , we demonstrated that 12-HHT is produced by TxAS-independent pathway in addition to a TxAS-dependent pathway both in vitro and in vivo. Effects of aspirin and ozagrel on the production of 12-HHT, TxB 2 , PGE 2 , and 12-HETE.
HEK293 cells pretreated with aspirin (ASA) or ozagrel were incubated with 10 µM arachidonic acid for 20 sec at 37°C and 12-HHT and eicosanoid levels were quantified.
Data represent the means ± S.E. (n = 3). **, p < 0.01 (unpaired t test). 
